Concomitant vaccination against hepatitis A and typhoid fever

Journal of Travel Medicine

Volumn 5, Issue 3, 1998, Pages 116-120

  Van Hoecke, Christian ^a   Lebacq, Edouard ^b   Beran, Jiri ^c   Prymula, Roman ^c   Collard, Françoise ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b Clinique Notre Dame de Grace   (Belgium)

^c Institute of Radiobiology and Immunology   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; TYPHOID VACCINE; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HEPATITIS A; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; TYPHOID FEVER; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; MALE; MIDDLE AGED; SALMONELLA TYPHI; TYPHOID-PARATYPHOID VACCINES; VACCINES, INACTIVATED; VIRAL HEPATITIS VACCINES;

EID: 0031668504     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1708-8305.1998.tb00483.x     Document Type: Article

References (16)

1. Hadler SC. Global impact of hepatitis A virus infection; changing patterns. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver diseases. Baltimore, MD: William and Wilkins, 1991:14-20.
2. Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 1992; 10:15-17.
3. Deinhardt F. Prevention of viral hepatitis A: past, present and future. Vaccine 1992; 1:10-14.
4. André F. Hepatitis A in travellers: a development of a safe, immunogenic and efficious inactivated vaccine. Travel Med Int 1995; 13:10-14.
5. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull WHO 1994; 72:957-971.
6. Levine MM. Typhoid fever vaccines In: Plotkin SA, Mortimer EA, eds. Vaccines. USA: WB Saunders, 1994: 597-633.
7. Plotkin SA, Bouveret-Le Cam NA. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch Intern Med 1995; 155:2293-2299.
8. Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella typhi: a worldwide epidemic Clin Infect Dis 1997; 24:106-109.
9. Jelinek T, Nothdurft HD, von Sonnenburg F, Löscher T. Risk factors for typhoid fever in travelers. J Travel Med 1996; 3:200-203.
10. Steffen R. Hepatitis A in travelers: the European experience. J Infect Dis 1995; 171:24-28.
11. Wolfe SM. Hepatitis A and the American traveler. J Infect Dis 1995; 171:29-32.
12. Horng Y-W, Chang M-W, Lee C-Y, et al. Safety and immunogenicity of hepatitis A vaccine in healthy adult volunteers. J Gastroenterol Hepatol 1993; 8:338-341.
13. André F, D'Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary findings. Vaccine 1992; 10:160-168.
14. Bienzle U, Bock HL, Kruppenbacher JP, Hoffmann F, Clemens R. Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interferences with other "travellers" vaccines with the immune response. Vaccine 1996; 14:501-505.
15. Gil A, Gonzáles A, Dal-Ré R, Calero JR. Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1140 EL.U). A controlled study in adults. Vaccine 1996; 14:1028-1030.
16. Gupta A. Multidrug-resistant typhoid fever in children: epidemiology and therapeutic approach. Pediatr Infect Dis J 1994; 13:134-140.